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Abstract The endocannabinoid system remains an attrac-
tive molecular target for pharmacological intervention due
to its roles in the central nervous system in learning,
thinking, emotional function, regulation of food intake
or pain sensation, as well as in the peripheral nervous
system, where it modulates the action of cardiovascular,
immune, metabolic or reproductive function. α/β hydro-
lase domain containing 6 (ABHD6)—an enzyme forming
part of the endocannabinoid system—is a newly discov-
ered post-genomic protein acting as a 2-AG (2-
arachidonoylglycerol) serine hydrolase. We have recently
reported a series of 1,2,5-thiadiazole carbamates as potent
and selective ABHD6 inhibitors. Here, we present com-
parative molecular field analysis (CoMFA) and molecular
dynamics studies of these compounds. First, we per-
formed a homology modeling study of ABHD6 based on
the assumption that the catalytic triad of ABHD6 com-
prises Ser148–His306–Asp 278 and the oxyanion hole is
formed by Met149 and Phe80. A total of 42 compounds
was docked to the homology model using the Glide mod-
ule from the Schrödinger suite of software and the select-
ed docking poses were used for CoMFA alignment. A
model with the following statistics was obtained:
R2 = 0.98, Q2 = 0.55. In order to study the molecular
interactions of the inhibitors with ABHD6 in detail, mo-
lecular dynamics was performed with the Desmond pro-
gram. It was found that, during the simulations, the hy-
drogen bond between the inhibitor carbonyl group and the
main chain of Phe80 is weakened, whereas a new hydro-
gen bond with the side chain of Ser148 is formed, facil-
itating the possible formation of a covalent bond.
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Introduction
The endocannabinoid signaling system (ECS) regulates
diverse physiological processes and has attracted signif-
icant attention as a potential drug target [1]. The ECS is
engaged in many pathophysiological conditions in cen-
tral and peripheral tissues. It is involved in the hormonal
regulation of food intake, cardiovascular, gastrointesti-
nal, immune, behavioral, antiproliferative and mammali-
an reproductive functions [2]. The ECS has also been
linked with drug addiction [3] and alcoholism [4] while
the dysregulation of ECS has been correlated to obesity
and metabolic syndrome pathogenesis [5]. Also, the ECS
has been linked to previously characterized phenomena called
depolarization-induced suppression of inhibition (DSI) and
depolarization-induced suppression of excitation (DSE) [6,
7]. Via DSI/DSE, the ECS acts as an important retrograde
modulator system controlling the extent of neuronal
excitability.
The key ligands of the endocannabinoid system are the
l ip id t r ansmi t t e r s N - a rach idonoy le thano lamine
(anandamide) and 2-arachidonoylglycerol (2-AG), which
activate the two major cannabinoid receptors CB1 and
CB2 [1, 2]. According to current knowledge, the lifetime
of 2-AG is regulated by three enzymes belonging to the
me t abo l i c s e r i n e hyd ro l a s e f am i l y. O f t he s e ,
monoacylglycerol lipase (MGL) is, on a quantitative ba-
sis, the main 2-AG hydrolase [8–10]. Two other hydro-
lases, α/β-hydrolase domain containing 6 (ABHD6) and
12 (ABHD12) have been identified recently [11, 12].
They are responsible for approximately 15 % of 2-AG
hydrolysis in the brain. ABHD6 is an integral membrane
protein of 30 kDa [13]. The active site of ABHD6 is
suggested to be directed into the interior of the cell, which
would make it possible to control the level of intracellular
2-AG [13]. Although the physiological and pathophysio-
logical significance of this enzyme is largely unknown, it
is proposed that high expression of ABHD6 is linked to
some forms of cancer [13].
Unlike MGL, ABHD6 and ABHD12 are still poorly
characterized, due mainly to the lack of selective in-
hibitors. Their more detailed physiological and patho-
physiological mapping requires development of highly
selective and potent pharmacological tools. To date,
only a few inhibitors of ABHD6 have been reported
(Fig. 1) [14–19].
Modern computer-aided approaches can be helpful in
the discovery of compounds with designed affinity pro-
files. Quantitative structure–activity relationships
(QSAR) have been used extensively in the development
of relationships between the physicochemical properties
of chemical entities and their biological activities to ar-
rive at reliable statistical models for the prediction of
activities of novel chemical compounds [20]. The key
assumption in this approach is that changes in structural
properties are connected with differences in the biologi-
cal activities of the compounds [20]. Three-dimensional
(3D)-QSAR has been developed as a logical continuation
of the widely used Hansch and Free-Wilson methods. It
examines the 3D features of the compounds to predict
their biological activities, applying robust chemometric
techniques such as partial least squares (PLS), genetic
partial least squares (G/PLS), artificial neural network
(ANN), etc. [20]. 3D-QSAR approaches, including com-
parative molecular field analysis (CoMFA) [21] and
comparative molecular similari ty index analysis
(CoMSIA) [22] make an important contribution to drug
design through deriving structural information in inter-
active fields and predicting the influence on activity
[23]. In particular, CoMFA is a well-established tech-
nique of 3D-QSAR [20, 24]. To the best of our knowl-
edge, our study is the first attempt to develop a CoMFA
model for ABHD6 inhibitors.
Nowadays, diverse techniques of molecular dynam-
ics (MD) constitute important computational tools with
which to study protein drug targets and their interac-
tions with ligands at a molecular level, particularly for
examining the motion of individual atoms, which can
be tracked over time [23]. In spite of successful at-
tempts to construct homology models of ABHD6 [19,
25], and to use molecular docking to build complexes
with inhibitors, no MD studies have been reported for
this enzyme.
We have recently developed a series of 1,2,5-thiadiazole
carbamates as potent and selective ABHD6 inhibitors [19].
Here, we present CoMFA and MD studies of these com-
pounds and several novel compounds.
Computational methods
Homology modeling and molecular docking
A homology model of ABHD6 was constructed as pre-
viously reported using Discovery Studio v. 3.5 [19]. We
assumed in our homology modeling studies that the cat-
alytic triad of ABHD6 comprises Ser148–His306–
Asp278, and the oxyanion hole is formed by Met149
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and Phe80. Among the current template structures avail-
able, the crystal structure of MenH (2-succinyl-6-hy-
droxy-2,4-cyclohexadiene-1-carboxylate synthase—a
hydrolase from the α/β hydrolase fold family—PDB
ID: 2XMZ [26]) resulted in optimal active site geometry
for docking studies. The compounds investigated (1–
42), including previously published [19] and new com-
pounds, were modeled using the LigPrep protocol from
the Schrödinger Suite software [27]. In order to sample
different protonation states of ligands at physiological
pH, the Epik module was used [28]. The compounds
were docked to the homology model using the standard
precision (SP) module Glide from the Schrödinger Suite
software. Prior to Glide docking studies, the grid box
was centered on the closest active site residues in the
case of the ABHD6 model (Phe80, Ser148, Met149,
Ile203, His 306). The hydrogen bond constraint Bat least
one^ to main chain amides of oxyanion hole residues
Met149 and Phe80 was used. The selected docking
poses were used for CoMFA alignment.
CoMFA studies
The compounds were divided into a training (35 com-
pounds) and a test (7 compounds) set. To construct 3D-
QSAR models, both training and test set compounds
should span at least four orders of activity magnitude
and be well proportioned in each activity magnitude
[29]. Both sets covered a reasonable distribution of the
biological data. The activity of the compounds was ei-
ther published elsewhere [19] or is included in the
Supplementary Information. The IC50 of compounds
was not determined experimentally but was calculated
as IC50-single from the residual activity according to the
following formula as reported previously [30]:
IC50−single ¼ I  Rð Þ= 100−Rð Þ
where I denotes the concentration at which residual ac-
tivity R was measured. For compound 42, with no inhi-
bition, an IC50 value of 100,000 nM was assumed. The
IC50 (nM) values were converted into pIC50 values,
which were applied as dependent variables for subse-
quent 3D-QSAR analyses.
Molecular alignment, which has a significant effect on 3D-
QSAR models, is the most sensitive factor [29]. In this study,
by identifying the binding conformations of the compounds,
molecular alignment was obtained through molecular
docking. Thus, all the molecules were well aligned in the
binding site of ABHD6 for developing the 3D-QSAR model.
The CoMFA model was developed by applying the QSAR
module in Sybyl v. 2.1. The standard Tripos force field was
used for CoMFA analysis with Gasteiger-Hückel point
charges and the default sp3 carbon probe with point charge +
1.0 [29]. The optimal number of components was designated
so that cross-validated R2 (Q2) values were maximal and the
standard error of prediction was minimal [29].
PLS analysis was applied to correlate the CoMFA fields
linearly to pIC50 activity values. A cross-validation analysis
was performed using the leave-one-out (LOO) method, in
which one compound is removed from the data set, and its
activity is predicted using the model derived from the remain-
ing compounds [29]. The model resulting in the highest Q2,
optimum number of components (ONC), and the lowest stan-
dard error of prediction were taken for further analysis. In
addition, the statistical significance of the model was
Fig. 1 Known inhibitors of α/β-hydrolase domain containing 6 (ABHD6) [14–19]
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13 [19] 7.07 7.14 -0.07
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Table 1 (continued)
15 [19] 6.83 6.99 -0.16
16 [19] 6.71 6.69 0.02
18 [19] 6.58 6.47 0.11
19 [19] 6.39 6.59 -0.20
20 [19] 6.34 6.48 -0.14
21 [19] 6.33 6.30 0.03
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described by the standard error of estimate (SEE) and proba-
bility value (F value) [29].
The predictive capability of the 3D-QSAR model was eval-
uated with the external test set of seven compounds. Moreover,
Table 1 (continued)
23 [19] 6.04 5.79 0.25
25 [19] 5.90 5.97 -0.07
26 [19] 5.84 5.91 -0.07
27 5.82 5.65 0.17
28 [19] 5.82 5.87 -0.05
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Table 1 (continued)
31 5.71 5.77 -0.06
32 5.63 5.52 0.11











36 [19] 5.25 5.23 0.02
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a progressive scrambling validation test was also performed
[31, 32]. The test set molecules were also optimized and aligned
in the samemanner as described above, and their activities were
predicted using the model developed.
Table 1 (continued)
40 4.80 5.00 -0.20
41 [19] 4.62 4.81 -0.19












17 [19] 6.58 7.32 -0.74
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Molecular dynamics
MD studies of selected ligand–inhibitor complexes were per-
formed using Desmond v. 3.0.3.1 [33]. The complex was hy-
drated and ions were added to neutralize protein charges and
then to a concentration of 0.15 M NaCl. The complex was
minimized and subjected to MD first in the NVT ensemble
for 1 ns and then in NPT ensemble for 20 ns with restrictions
on the protein backbone in each case. The production run was
performed for 100 ns in the NPTensemble with no restrictions.
Results and discussion
The studied compounds
The studied ABHD6 inhibitors 1–42 accompanied by
ABHD6 inhibitory activity (experimental and predicted) are
presented in Table 1. The compounds were divided into train-
ing set (35 compounds) and test set (7 compounds: 11, 17, 24,
30, 34, 37, 39). Most compounds have been published previ-
ously [19]; however, some compounds are reported for the
first time (3, 12, 27, 29–33, 38, 40, 42). The synthesis, exper-
imental data and details of the ABHD6 activity determination
are presented in the Supplementary Information.
Molecular docking
Homology models of ABHD6 were previously successful-
ly applied to the molecular docking of inhibitors [19, 25].
Compounds 1–42 were thus all docked into the binding
site of human ABHD6. Among the Glide docking poses,
those in which the carbonyl group interacted with Phe80
were selected and used for molecular alignment. The final
binding poses of compounds 1 (the most active com-
pound) and 6 (the most promising compound from our
Table 1 (continued)
30 5.73 6.89 -1.16
34 [19] 5.31 7.50 -2.19
37 [19] 5.09 6.63 -1.54
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previous article [19]) are presented in Fig. 2. It can be
seen that the catalytic triad of ABHD6 comprises
Ser148–His306–Asp278, and the oxyanion hole is formed
by Met149 and Phe80 [19]. The most important inhibitor
contact is a hydrogen bond between the carbonyl group of
the ligand and the main chain of Phe80.
Molecular alignment
The quality of 3D-QSAR models is sensitive to the molecular
alignment as inhibitory activity correlates strongly with differ-
ent substitutions on a specific point in the same compound
series [29]. The common structure has been used widely as a
base for molecular alignment [20, 24]. However, better results
can be obtained when 3D-QSAR models are constructed and
evaluated on the active conformations of training and test set
compounds, in particular when similar ligands occupy differ-
ent binding poses in the binding pocket [34]. The molecular
alignment of the compounds from the training and test sets is
shown in Fig. S1 in the Supplementary Information. The spa-
tial positions of the scaffolds were not kept still in the align-
ment as is usually the case in docking-based alignment [29];
however, they are within an acceptable range of displacement.
This may be caused by the situation that, in reality, different
bioactive conformations can be adopted by these derivatives
as a result of different substituted groups [29]. Moreover,
Fig. 2 The docking poses of 1 (a, b) and 6 (c, d) in the binding pocket of ABHD6 selected for molecular alignment. a, cOverview of the complex; b, d
details of the binding pocket
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alignment using docking conformations will also facilitate our
understanding of contour maps of the models in a structure-
based manner [29].
CoMFA statistics
The 3D-QSAR CoMFA model was built using Sybyl-X v.
2.1. The CoMFA model gave a cross-validated coefficient
Q2 of 0.55 with an optimal component of 4, R2 of 0.98
and an F value of 346.762. The field contributions of
parameters were 65.3 % and 34.7 % for the steric field
and the electrostatic field descriptor, respectively. These
statistical parameters indicate that the CoMFA model is
statistically significant. Experimental and predicted IC50
values are presented in Table 1. It can be seen that they
do not deviate significantly from each other (generally not
more than 1 logarithmic unit). Figure 3 shows a very good
correlation between the experimental and computed IC50
values for the training set, but a worse correlation for the
test set. Most compounds from the training set were over-
predicted. However, the value of the cross-validated coef-
ficient Q2 (above 0.5) indicates the good internal predict-
ability of the model.
Validation of CoMFA model
As the first step in validation, the IC50 of the seven com-
pounds from the test set was predicted (Table 1). It can be
seen that two most active compounds from the test set (11
and 17) are predicted correctly within acceptable error.
The activities of the five less active compounds are pre-
dicted higher than they should be, probably due to the fact
that their IC50 was estimated only as IC50-single.
Furthermore, a progressive scrambling test was performed
as an additional validation. The Q2 statistic returned is an
estimate of the predictivity of the model after removing
the effects of redundancy [35]. It is computed by fitting
the correlation of scrambled to unscrambled data (R2yy)
to the cross-validated correlation coefficient (Q2) (calcu-
lated after each scrambling performed) applying a 3rd
order polynomial equation [35]. The cSDEP statistic is
an estimated cross-validated standard error at a specific
critical point (0.85 default used in this study) for R2yy,
and is computed from a 3rd order polynomial equation
that fits the scrambled results [35]. The slope of Q2 with
respect to R2yy is reported as dQ2/dR2y, and is known as
the critical statistic [35]. It shows to what extent the mod-
el changes in response to small changes to the dependent
variable [35]. In a stable model, dQ2/dR2yy should not
exceed 1.2 (ideally 1) [35]. This method was employed
for the CoMFA model to verify the number of compo-
nents used to build the model and to check the cross-
validation against the possibility of such a redundancy
in the training set [35]. Table 2 lists the results of the
progressive scrambling of the CoMFA model. Q2 values
above 0.35 are reported to indicate that the original, un-
perturbed model is robust [32].
Fig. 4 CoMFA steric and electrostatic contour fields. Fields drawn with
85/15 proportion of favorable and unfavorable interactions. The most
active compound (1) is shown
Table 2 Progressive scrambling test results for the comparative
molecular field analysis (CoMFA) model
Component Q2 cSDEP dQ2/dR2yy
2 0.49 0.71 −0.16
3 0.49 0.72 0.19
4 0.49 0.74 0.19
5 0.51 0.72 0.21
6 0.48 0.76 0.32
7 0.52 0.74 0.66
Fig. 3 Experimental versus predicted pIC50 values for the training and
test sets
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Table 3 Suggested modifications of compound 1. Experimental valuea
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Contour map
Figure 4 shows the steric and electrostatic contour maps gen-
erated via CoMFA modeling. Steric contour maps give infor-
mation about the spatial volume of substituted groups at dif-
ferent positions. There were three green and one yellow con-
tour regions located in the active site, with green meaning
bulky groups are favored and yellow meaning bulky groups
are disfavored. The yellow contour map may explain the low-
er activity of compounds 27, 28, 31, 33, 36 and 40, which
have a bulky substituent in this position. Interestingly, there is
a red contour region near the carbonyl group, meaning that
less negative charge would be favored here. This is probably
not connected with the sp2 hybridized oxygen atom but with
the polarizability of the whole area. Importantly, the carbonyl
group is a key moiety interacting with the active site of
ABHD6 as the most important inhibitor contact is a hydrogen
bond between the carbonyl group of the ligand and the main
chain of Phe80 (Fig. 2). This contour may be a false property
generated by CoMFA as there is a lack of diversity of com-
pounds in this region, therefore no contours should be present
there.
Directions of inhibitor modifications
On the basis of the constructed CoMFA model, some modifi-
cations of compound 1 were suggested. The proposed modi-
fications, i.e., compounds 43–47, are presented in Table 3. It
can be concluded that changing the piperidine moiety into
morpholine results in the equipotent compound 43. It was
found that introducing an electron-donating group in the meta
or preferably the para position of the phenyl group
Fig. 5 Changes in potential energy of the complex during simulations of
the complex of 6 and ABHD6
Fig. 6 a,b Root mean square deviations (RMSD) during molecular
dynamics (MD) simulations. a Inhibitor 6 RMSD compared to initial
position. b Complex RMSD compared to initial position
Fig. 7 Protein backbone root mean square fluctuation (RMSF) during
simulation
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(compounds 44–47) leads generally to enhancement of activ-
ity. The strongest effect was observed with an amino group in
both meta and para position. In contrast, an electron-
withdrawing group resulted in an activity drop (data not pre-
sented). A similar effect was found when the N-methyl group
was replaced by the N-ethyl or propyl group or when an ad-
ditional methyl group was added in the benzylic position.
Molecular dynamics
The investigated compounds are irreversible inhibitors of
ABHD6. In order to study the first events of inhibitor
binding, before formation of a covalent bond between
the ligand carbonyl group and a side chain of Ser148
[17, 25]. MD simulations were performed for the complex
of compound 6 with ABHD6. The complex was stable
during simulations, as demonstrated by the decreasing
value of potential energy for the complex (Fig. 5) and
the complex RMSD (Fig. 6b). The position of 6 in the
binding site of ABHD6 was relatively stable, as indicated
by the ligand RMSD value below 3 Å (Fig. 6a). Figure 7
shows protein backbone RMSF during simulation. The
greatest RMSF value (over 4 Å) has been found for helix
end Gly193-Ser194 and Val224. During simulations it
was observed that the distance between ligand carbonyl
group and the main chain of Phe80 is increasing, weak-
ening the respective hydrogen bond (Fig. 8). In contrast, a
bond between the ligand carbonyl group and Ser148 is
formed and maintained during the simulation. Although
the distance is slightly increasing, there is a possibility
to form a covalent bond necessary for irreversible inhibi-
tion (Fig. 8).
Conclusions
We constructed a 3D QSAR model for new inhibitors of
ABHD6 that represents the first CoMFA model for this
enzyme. The model allowed us to explain the lack of
activity of the least active compounds caused by unfa-
vorable steric interactions. Moreover, we performed MD
simulations and showed that formation of an additional
hydrogen bond between the ligand carbonyl group and
Ser148 in the early stages of ligand binding may facili-
tate the covalent bond formation that is necessary for
irreversible inhibition.
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